Mobile

A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with a...

Update Il y a 4 ans
Reference: EUCTR2006-006068-44

A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with amlodipine 10 mg in patients with essential hypertension not adequately responsive to amlodipine 10 mg monotherapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Demonstrate the efficacy of the combination therapies of aliskiren/amlodipine (150/10 mg and 300/10 mg), in hypertensive patients who do not adequately respond to a 4-week treatment of amlodipine 10 mg by testing the hypothesis of superior reduction in mean sitting diastolic blood pressure (msDBP) from baseline to end of study when compared to amlodipine 10 mg monotherapy.

Inclusion criteria

  • Hypertension

Links